PTPRC and sarcoma: In one approach, we used general markers of the mesenchymal phenotype and established a cut-off of the number of CD45- cells in blood from healthy donors; then we scored blood specimens of patients with sarcoma, showing a greater number of putative sarcoma cells present in the patients compared to the healthy donors.